Oura Health filed for an IPO in May at an $11 billion valuation—a clean exit window for a company that started as a biohacking sleep tracker. But the real strategic inflection happened alongside: the FDA relaxed its oversight of wearables for blood pressure and glucose monitoring[1], permitting features to ship without premarket review. Within days, Oura announced a cuffless blood-pressure capability baked into the Ring 5, paired with AI-enabled predictive health models. This moves Oura from consumer wellness into clinical-grade monitoring territory—though the regulatory ease is both opportunity and threat. The blood-pressure feature won't face FDA premarket scrutiny, meaning fast time-to-market. But that same path is now open to every wearable maker, CGM vendor, and even smartphone app. already owns glucose; runs clinical programs around hypertension and diabetes management. The category is about to have dozens of entrants, each claiming "passive," "continuous," "AI-powered." The real question isn't whether Oura can add a blood-pressure sensor—it's whether a form factor (a ring) and a dataset (1M+ users' continuous physiological history) can create a defensible position in chronic disease. Oura's advantage is passive, real-time data collection and behavioral triggers (sleep, stress, resting heart rate) that correlate with hypertension control. But that's a product advantage, not a moat. Payers, health systems, and employers care about outcomes and cost reduction, not sensor elegance. If Oura can show that predictive rings reduce ER visits or hospitalizations, it becomes a clinical asset. If it's just a faster readout of what a cuff already shows, it's a feature. The IPO filing suggests Oura's founders believe they have the former; the analyst community will spend the next 18 months deciding if they're right.